Objective To investigate the relationship between SonoVue ablation enhancement effects on high-intensity focused ultrasound (HIFU) and the concentration of SonoVue and timing of HIFU.
Results
In the experimental study, the highest temperature and the largest necrotic volume in the liver were observed when HIFU sonication started at 60 seconds after administration of SonoVue. In the clinical study, the rate of significant grey-scale changes in the 1-minute SonoVue group was significantly greater than in the other three groups. The sonication time to reach massive greyscale changes measured in the 1-minute SonoVue group was significantly shorter than in in the other three groups. The sonication time for ablating 1 cm 3 of fibroid volume in the 1-minute SonoVue group was significantly shorter than in the other three groups. The acoustic energy used in treating 1 mm 3 of uterine fibroid in the 1-minute SonoVue group was significantly less than that used in the other three groups. No major complications occurred in this study.
Introduction
As a non-invasive technique, high-intensity focused ultrasound (HIFU) has been widely used in treating different types of solid tumours. [1] [2] [3] However, in clinical practice, we have found that HIFU treatment is time-consuming in some cases. Therefore, improving treatment efficacy is a challenge in HIFU clinical applications.
Over the last 10 years, ultrasound contrast agents have been used in tumour diagnosis and evaluation of the therapeutic results of radiofrequency ablation (RFA) or HIFU treatment. [4] [5] [6] [7] As microbubbles can change the acoustic properties of tissues and thus increase the efficacy of HIFU treatment, many experimental studies have investigated the enhancing effects of microbubbles on HIFU treatment. 8, 9 Peng et al. 10 and Jiang et al. 11 have demonstrated that SonoVue can be safely used to enhance the ablation effects of HIFU for uterine fibroids. But in those studies, HIFU sonication began 5 or 10 minutes after the administration of SonoVue. To the best of our knowledge, no study has been performed to test the best time point to begin HIFU treatment after SonoVue administration. Therefore, we designed a study to find this optimal time point through animal experiments, and then performed a clinical study to investigate efficacy and safety.
Materials and methods
The animal study protocol was approved by our animal ethics committee and the clinical study was approved by the ethics committee at our university. Every patient provided a signed informed consent before the HIFU procedure.
Animal study
Sixty-three rabbits (Chongqing Medical University, China) 2.0-2.5 kg were used in this experiment. Three rabbits, as a control group, were treated using only MRgHIFU. The other 60 rabbits were evenly assigned to three groups (0.03 ml/kg group, 0.05 ml/kg group or 0.07 ml/kg group) according to the intravenous concentration of SonoVue. The sonication began at 10, 30, 60, 90, 120, 150, 180, 210, 250 or 300 seconds after the administration of SonoVue, with two rabbits in each group ablated at each time point. The procedure was performed under general anaesthesia using 3% pentobarbital solution (1 ml/kg) and 40 mg/l vecuronium bromide (0.04 mg/kg) via the rabbit's ear vein. Before HIFU ablation, the hair on the abdominal wall was shaved and the skin was degreased and degassed with 70% ethanol solution.
Clinical study
From September 2013 to January 2015, 143 women with a solitary uterine fibroid were enrolled in this study. Among them, 30 were assigned to the control group, 32 to a group in which sonication occurred 1 minute after administration of SonoVue, 38 to sonication for 3 minutes after administration of SonoVue, and 43 to sonication 5 minutes after administration of SonoVue. The average age of patients in the control group, 1, 3 and 5 minutes after SonoVue group was 43.5 AE 1.1 years (range 25-52), 41.0 AE 1.0 years (range 25-52), 42.6 AE 1.1 years (range 28-52), and 42.9 AE 0.9 years (range 31-52), respectively ( Table 1) .
All patients underwent pretreatment MR imaging with a standardised protocol to help confirm the size, volume, location and enhancement of fibroids. The details have been described in a previous publication.
11
Microbubble ultrasound contrast agent SonoVue (Bracco, Milan, Italy) is a phospholipid-shelled ultrasound contrast agent containing sulphur hexafluoride. This is the only ultrasound contrast agent approved by China Food and Drugs Administration.
Before administration, SonoVue was first reconstituted following the manufacturer's instructions with the addition of 5 ml of normal saline. In the experiment, the rabbits in the SonoVue group were administrated a bolus of SonoVue at 0.03, 0.05 and 0.07 ml/kg. In the clinical study, the patients in the SonoVue groups were administrated a bolus of 2.0 ml SonoVue solution before HIFU treatment. Every rabbit was positioned in prone position on the HIFU table with the abdominal wall in contact with degassed water. The rabbit livers were pre-scanned by MRI T2-weighted imaging (T2WI) in both sagittal and transverse views. Two points in each liver were selected for sonication. The distance between the two target points was greater than 10 mm to avoid heat spreading, which may affect the results. Point scan was used, at 300 W for 5 seconds. The distance from skin to target was 20 mm. SonoVue bubbles usually disappear 6 min after the bolus injection in a body, so we designed the intervals between the administration of SonoVue and HIFU sonication to be 10, 30, 60, 90, 120, 150, 180, 210, 250 and 300 seconds. Real-time MRI temperature was monitored by the GRE-T-MAP sequences during HIFU sonication. The procedure was performed under general anaesthesia and endotracheal intubation was used.
USgHIFU after administration of SonoVue
The clinical study was performed with the JC tumor therapeutic system [Chongqing Haifu (HIFU) Medical Tech Co., Ltd.]. The ultrasound beams were produced by a 20-cm diameter transducer with a focal length of 15 cm, operated at a frequency of 0.8 MHz. A 1.0-8.0 MHz diagnostic US probe (MyLab 70, Esaote, Genova, Italy) located at the centre of the therapeutic transducer was used to monitor the treatment.
The HIFU treatment protocol has been described in previous studies. 10, 11 Briefly, every patient was carefully positioned prone on the HIFU table. The anterior abdominal wall was in contact with degassed water. HIFU treatment was performed under intravenous conscious sedation. During the procedure, every patient was asked to report any discomfort. Patients in the control group accepted HIFU treatment alone; patients in the SonoVue groups were administered a bolus of 2.0 ml SonoVue at 1, 3 or 5 minutes before HIFU sonication and thus defined as the 1-minute, 3-minute or 5-minute SonoVue group, respectively. Point sonication with 400 W sonication power was used. The treatment terminated when grey-scale change at the target region covered the entire fibroid.
Assessment of therapeutic effects of animal study
Two days after HIFU treatment, the rabbits were euthanised. The treated tissue was carefully sectioned, and coagulative necrosis was evaluated. The long-axis and short-axis of coagulative necrosis were measured by calipers. The volume of coagulative necrosis was calculated according to the following equation: V = p 9 L 9 W 2 /6 (L: length, W: width).
Evaluation of clinical study
In the clinical study, all patients received post-treatment MRI 1 day after HIFU to evaluate therapeutic effectiveness. The tumour size and the non-perfused volume (NPV) were measured using T2WI or contrast-enhanced images. Fractional ablation (defined as the NPV divided by the fibroid volume) was calculated. Two experienced radiologists analysed all of the images independently.
Statistical analysis
SPSS software (SPSS 19; IBM SPSS, IL, USA) was used for statistical analysis. Data were reported as mean AE SD or median. Kruskal-Wallis test, independent sample t-test or Chi-square test were used for statistical comparisons among groups. A P-value <0.05 was considered to indicate a significant difference.
Results

Effects of SonoVue on temperature change and necrosis volume
Using the same sonication power and sonication time, the mean temperature achieved at the target points was 56.7 AE 1.8°C in the control group. The average temperatures achieved at the target points at 10, 30, 60, 90, 120, 150, 180, 210, 250 and 300 seconds after administration of SonoVue were respectively 56. .6°C, (0.07 ml/kg group). Temperatures presented a parabolic trend over time, and the highest temperature was achieved 60 seconds after the administration of SonoVue in each group. The temperature 60 seconds after the administration of SonoVue in the 0.05 ml/kg group was similar to that in the 0.07 ml/kg group, whereas the temperature in the 0.03 ml/kg group was significantly lower than the other two groups (Table 1, Figures 1 and 2) .
The shape of the target points was classified as spherical, and the demarcation between necrotic and viable tissues was sharp. The mean necrotic volume was 22.92 AE 0.81 mm 3 Figures 3 and 4) . We set the temperature of each time point as abscissa and the necrotic volume of each time point as ordinate. A trendline between them was calculated, with regression equation y = 2.3009x À 104.41 (R² = 0.6216) (0.03 ml/kg group), y = 3.2477x À 167.74 (R² = 0.9113) (0.05 ml/kg group) and y = 4.927x À 279.06 (R² = 0.9251) (0.07 ml/kg group), respectively. The greatest goodness of fit (R² = 0.9251) was observed in the 0.07 ml/kg group ( Figure 5 ). Table 3 shows the baseline characteristics of the 143 patients. In the control group of the 30 patients, the fibroids ranged from 2.6 to 6.0 cm (median 4.2) in diameter. Among them, 16 (53.3%) fibroids were located at the anterior wall of uterus, eight (26.7%) at the posterior wall, one (3.3%) at the fundus, and five (16.7%) at the lateral wall. Based on the signal intensity of T2WI, two (6.7%) fibroids were subjectively classified as hyperintense, six (20.0%) as isointense, 17 (56.7%) as hypointense, and six (16.7%) as mixed intensities. In the 1-minute SonoVue group, the 32 fibroids ranged from 1.4 to 7.5 cm (median 5.2) in diameter. Among them, 14 (43.8%) fibroids were located at the anterior wall of uterus, nine (28.1%) at the posterior wall, one (3.1%) at the fundus, and eight (25.0%) at the lateral wall. Based on the signal intensity of T2WI, six (18.8%) fibroids were subjectively classified as hyperintense, three (9.4%) as isointense, 12 (37.5%) as hypointense, and 11 (34.4%) as mixed intensities. In the 3-minute SonoVue group, the 38 fibroids ranged from 2.7 to 11.8 cm (median 6.1) in diameter. Of these, 16 (42.1%) fibroids were located at the anterior wall of uterus, seven (18.4%) at the posterior wall, and 15 (39.5%) at the lateral wall. Based on the signal intensity of T2WI, six (15.8%) fibroids were subjectively classified as hyperintense, four (10.5%) as isointense, 18 (47.4%) as hypointense, and ten (26.3%) as mixed intensities. In the 5-minute SonoVue group, the 43 fibroids ranged from 2.0 to 13.7 cm (median 5.7) in diameter. Of these, 19 (44.2%) fibroids were located at the anterior wall of uterus, 13 (30.2%) at the posterior wall, two (4.7%) at the fundus, and nine (20.9%) at the lateral wall. Based on the signal intensity of T2WI, six (14.0%) fibroids were subjectively classified as hyperintense, two (4.7%) as isointense, 19 (44.2%) as hypointense, and 16 (37.2%) as mixed intensities. No significant differences in fibroid size, tumour locations or signal intensity of T2WI were observed.
Patients and lesions
Grey-scale value changes
In the control group, massive grey-scale change was observed in 16 of 30 lesions (53.3%); the median sonication time to reach massive grey-scale change was 922 seconds (range 18-1660). In the 1-minute SonoVue group, massive grey-scale change was observed in 28 of 32 lesions (87.5%); the median sonication time to reach massive greyscale change was 6 seconds (range 1-713). In the 3-minute SonoVue group, massive grey-scale change was observed in 27 of 38 lesions (71.1%); the median sonication time to reach massive grey-scale change was 114 seconds (range 5-713). In the 5-minute SonoVue group, massive grey-scale change was observed in 26 of 43 lesions (60.5%); the median sonication time to reach massive grey-scale change was 168 seconds (range 18-517). The rate of massive grey-scale change in the 1-minute SonoVue group was significantly greater than in the other groups (Chi-square test, P = 0.020) and the sonication time to achieve massive grey-scale change in the 1-minute SonoVue group was significantly shorter than the other groups (Kruskal-Wallis test, P = 0.020) ( Table 4 ).
Post-procedure evaluation
As presented in Table 4 , the median fibroid volume and NPV in the control group were 24.9 cm 3 (range 4.9-160.5) and 26. In the 5-minute SonoVue group, the median fibroid volume and NPV were 51. 3 of fibroid and the EEF in the 1-minute SonoVue group were significantly lower than that of the other groups (KruskalWallis test) (P = 0.002, P = 0.002) ( Table 4) . Data are numbers of fibroids and mean value AE SD or median value. No significant difference was observed among the four groups (P > 0.05). *A, anterior wall; P, posterior wall; F, fundus; L, lateral wall.
Adverse events during or post-procedure Table 5 shows that 6.7% (two of 30) of the patients in the control group, 3.1% (one of 32) in the 1-minute SonoVue group, 2.6% (one of 38) in the 3-minute SonoVue group, and 9.3% (four of 43) in the 5-minute SonoVue group complained of transient leg pain during HIFU sonication (P = 0.523). Sciatic or buttock pain was reported in 60.0% (18 of 30) of patients in the control group, 40.6% (13 of 32) in the 1-minute SonoVue group, 28.9% (11 of (Table 5 ). All patients were allowed to go home 1 day after HIFU treatment. They were recommended to take antibiotics for 1 week. The patients were contacted through hospital nurses daily in the first 3 days after HIFU, but no one reported any complications, which have previously led to substantial morbidity and disability corresponding to the unified standardised SIR grading system. 12 
Discussion
Several studies have shown that SonoVue seems to present in the rabbit liver 12-15 seconds after injection and is sustained at a stable high level for 1 minute. 8, 13 In this study, we used MR thermal mapping to measure the temperature at the target at different time points after sonication with the same power for the same sonication time, and found that the highest temperature occurred at the target point present 60 seconds after the administration of SonoVue. We further compared the effects of different concentrations of SonoVue on HIFU ablation. The average temperature at the target point was 102.5 AE 3.1°C, 60 seconds after administration of 0.05 ml/kg SonoVue and 103.9 AE 2.7°C 60 seconds after administration 0.07 ml/kg. However, the average temperature was 80.9 AE 2.5°C at the target point 60 seconds after administration of 0.03 ml/kg, significantly lower than in the other two groups. We therefore consider 60 seconds after the administration of SonoVue to be the optimal time point to enhance the ablation effect of HIFU in normal liver of rabbits. However, we did not find any significant difference between the 0.05 ml/kg group and the 0.07 ml/kg group. Thus, 0.05 ml/kg was considered the optimal concentration for enhancing HIFU ablation of rabbit liver.
In the present study, we also observed that the largest necrotic volume in the liver of rabbits was achieved 60 seconds after the administration of SonoVue during HIFU treatment. The largest necrotic volume 60 seconds after administration of SonoVue was in the group administered 0.07 ml/kg of SonoVue. Therefore, the optimal time point to enhance the ablation effects of HIFU is 60 seconds after the administration of SonoVue and the ablation effects were enhanced as the concentration of SonoVue increased. We speculated that complex cavitation effects were involved in enhancing the ablation effects. Therefore, thermal effects and cavitation were the main mechanisms of enhancing ablation effects of HIFU. 14, 15 We further performed regression analysis to test the relation between the temperatures and necrotic volumes, and found that the temperature change is consistent with the size of necrosis in the rabbit liver in the group with a SonoVue concentration of 0.07 ml/kg.
Previous studies have demonstrated that SonoVue can enhance the ablation effects of HIFU for uterine fibroids. 10, 11 Based on the results of the experimental study, we performed a clinical study to investigate which time point after administration of SonoVue is the most effective and safest in the treatment of uterine fibroids with HIFU. In this study, we started to treat patients at 1, 3 or 5 minutes after administration of SonoVue. The results showed that the rate of significant grey-scale changes in the 1-minute SonoVue group was significantly higher than in the other groups, and the sonication time to achieve massive grey-scale changes was significantly shorter than in the other groups. Many studies have shown that the significant grey-scale changes are reliable for monitoring the response to HIFU treatment. 10 Our results have demonstrated that utilising SonoVue could increase the rate of significant grey-scale changes and decrease sonication time for treating the same fibroid.
We further compared the treatment efficacy. It took significantly less time and less acoustic energy to ablate 1 cm 3 of fibroid in the group in which the fibroids were treated starting 1 minute after administration of SonoVue than in the other groups. In addition, the sonication time for ablating 1 cm 3 of fibroid and the EEF, increased with the metabolism of contrast agents, but they were significantly smaller than that of the control group. HIFU treatment starting 1 minute after administration of SonoVue may achieve the best enhancing effect of HIFU treatment for uterine fibroids.
Many studies have shown that SonoVue is a safe ultrasound contrast agent with a low incidence of complications. [16] [17] [18] We have also investigated whether SonoVue could be used safely to enhance the ablation effect of HIFU or to evaluate HIFU treatment. In this study, patients complained of intra-procedure leg, sciatic or buttock pain, discomfort on skin or treatment area pain, but no significant differences were observed among the four groups, and these adverse effects subsided within 3 days. No bowel injury, blood vessel injury, skin burn or nerve injury occurred. Our results demonstrate that SonoVue can be used safely to enhance the therapeutic effects of HIFU for uterine fibroids.
The mechanism of enhancing the ablation effect of SonoVue was due to thermal and cavitation effects of the microbubbles. 19, 20 In addition, exposure of the bubbles to the acoustic field of HIFU leads to violent collapse, which may have caused mechanical injury to the tissue at the target. In our study, both the experimental and the clinical study demonstrated that the best ablation effect can be obtained starting at 1 minute after the administration of SonoVue.
Conclusions
Based on the experimental and clinical study, we conclude that SonoVue can be used safely to enhance the ablation effects of HIFU treatment. The optimal time to begin treating uterine fibroids with HIFU sonication appears to be 1 minute after administration of SonoVue. 
